Mohamed Amine Jmel

Dr. Mohamed Amine Jmel

Laboratory of Genomics and Proteomics of Disease Vectors, Institute of Parasitology, Biology Centre CAS České Budějovice, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Energy Conversion and Management
Verified
Journal Article
Closed access
NYNesrine Ben Yahmed
Nesrine Ben Yahmed
MJMohamed Amine Jmel
Mohamed Amine Jmel
MAMonia Ben Alaya
Monia Ben Alaya
HBHassib Bouallagui
Hassib Bouallagui
MMM. Nejib Marzouki
M. Nejib Marzouki
ISIssam Smaali
Issam Smaali

1 October 2019 in Journal of Cleaner Production
Verified
Journal Article
Closed access
MJMohamed Amine Jmel
Mohamed Amine Jmel
NANico Anders
Nico Anders
GGhazi BEN MESSAOUD
Ghazi BEN MESSAOUD
MMMed Nejib Marzouki
Med Nejib Marzouki
ASAntje Spiess
Antje Spiess
ISIssam Smaali
Issam Smaali

Verified
Journal Article
Open access
PDF file
MAMuhammad Nadeem Abbas
Muhammad Nadeem Abbas
MJMohamed Amine Jmel
Mohamed Amine Jmel
IMImen Mekki
Imen Mekki
IDIngrid Dijkgraaf
Ingrid Dijkgraaf
Michail KotsyfakisMichail Kotsyfakis
Michail Kotsyfakis
Ticks can seriously affect human and animal health around the globe, causing significant economic losses each year. Chemical acaricides are widely used to control ticks, which negatively impact the environment and result in the emergence of acaricide-resistant tick populations. A vaccine is considered as one of the best alternative approaches to control ticks and tick-borne diseases, as it is less expensive and more effective than chemical controls. Many antigen-based vaccines have been developed as a result of current advances in transcriptomics, genomics, and proteomic techniques. A few of these (e.g., Gavac® and TickGARD®) are commercially available and are commonly used in different countries. Furthermore, a significant number of novel antigens are being investigated with the perspective of developing new anti-tick vaccines. However, more research is required to develop new and more efficient antigen-based vaccines, including on assessing the efficiency of various epitopes against different tick species to confirm their cross-reactivity and their high immunogenicity. In this review, we discuss the recent advancements in the development of antigen-based vaccines (traditional and RNA-based) and provide a brief overview of recent discoveries of novel antigens, along with their sources, characteristics, and the methods used to test their efficiency.

Verified
Journal Article
Open access
PDF file
MJMohamed Amine Jmel
Mohamed Amine Jmel
HVHanne Voet
Hanne Voet
RARicardo Nascimento Araújo
Ricardo Nascimento Araújo
LTLucas Tirloni
Lucas Tirloni
ASAnderson Sa-Nunes
Anderson Sa-Nunes
Michail KotsyfakisMichail Kotsyfakis
Michail Kotsyfakis
Kunitz domain-containing proteins are ubiquitous serine protease inhibitors with promising therapeutic potential. They target key proteases involved in major cellular processes such as inflammation or hemostasis through competitive inhibition in a substrate-like manner. Protease inhibitors from the Kunitz superfamily have a low molecular weight (18–24 kDa) and are characterized by the presence of one or more Kunitz motifs consisting of α-helices and antiparallel β-sheets stabilized by three disulfide bonds. Kunitz-type inhibitors are an important fraction of the protease inhibitors found in tick saliva. Their roles in inhibiting and/or suppressing host homeostatic responses continue to be shown to be additive or synergistic with other protease inhibitors such as cystatins or serpins, ultimately mediating successful blood feeding for the tick. In this review, we discuss the biochemical features of tick salivary Kunitz-type protease inhibitors. We focus on their various effects on host hemostasis and immunity at the molecular and cellular level and their potential therapeutic applications. In doing so, we highlight that their pharmacological properties can be exploited for the development of novel therapies and vaccines.

1 January 2016 in Carbohydrate Polymers
Verified
Journal Article
Closed access
MJMohamed Amine Jmel
Mohamed Amine Jmel
GGhazi BEN MESSAOUD
Ghazi BEN MESSAOUD
MMM. Nejib Marzouki
M. Nejib Marzouki
MMMohamed Mathlouthi
Mohamed Mathlouthi
ISIssam Smaali
Issam Smaali

31 August 2017 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
MJMohamed Amine Jmel
Mohamed Amine Jmel
NANico Anders
Nico Anders
NYNesrine Ben Yahmed
Nesrine Ben Yahmed
CSChristian Schmitz
Christian Schmitz
MMM. Nejib Marzouki
M. Nejib Marzouki
ISIssam Smaali
Issam Smaali